by synergycap1 | Jul 28, 2017 | Bad Credit Loans, Bank Lending, Business Lending, Business Loans, Capital, Economics, Finance, Non-Bank Loans, Working Capital
(Reuters) – U.S. stock index futures were lower on Friday as Amazon’s profit miss took a toll on technology shares. * Amazon’s (AMZN.O) shares were down 2.96 percent in premarket trading after it reported a 77 percent drop in profit as its rapid and...
by synergycap1 | Jul 28, 2017 | Bad Credit Loans, Bank Lending, Business Lending, Business Loans, Capital, Economics, Finance, Non-Bank Loans, Working Capital
SAN FRANCISCO (Reuters) – A flood of Snap Inc (SNAP.N) shares held back since the Snapchat owner’s initial public offering could start to trade freely next week, pressuring a stock that has already plunged far below its debut price. Starting on Monday and...
by synergycap1 | Jul 28, 2017 | Bad Credit Loans, Bank Lending, Business Lending, Business Loans, Finance, Startup, Working Capital
Writing and being able to persuade partners, investors, colleagues, and ultimately customers is the top skill to have when starting a business.
by synergycap1 | Jul 28, 2017 | Bad Credit Loans, Bank Lending, Business Lending, Business Loans, Capital, Economics, Finance, Non-Bank Loans, Working Capital
There is no one in charge in Congress but President Donald Trump has an opportunity to lead, former Government Accountability Office head David Walker told CNBC on Friday. “The truth is we have way too many wingnuts in Washington,” said Walker, who was...
by synergycap1 | Jul 28, 2017 | Bad Credit Loans, Bank Lending, Business Lending, Business Loans, Finance, Working Capital
The Association of American Railroads (AAR) reported this week that United States rail carloads and intermodal volumes were mixed annually for the week ending July 22.Carloads declined 2% to 256,863, which trailed the week ending July 15 at 262,869 and topped the week...
by synergycap1 | Jul 28, 2017 | Bad Credit Loans, Bank Lending, Business Lending, Business Loans, Capital, Economics, Finance, Non-Bank Loans, Working Capital
AstraZeneca saw more than £10 billion ($13.08 billion) wiped off its market value on Thursday, yet one of Britain’s most influential investors argued the pharma giant’s investment case remains “very, very attractive.” Shares in the ailing...
